BMS-1
Based on 32 publication(s) in Google Scholar
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.53%
- CAS No.: 1675201-83-8
- Formule: C29H33NO5
- Masse moléculaire:475.58
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Anti-Cancer Compound Library
HY-L025
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Peptidomimetic Library
HY-L033
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Heterocyclic Compound Library
HY-L138
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Gastric Cancer Compound Library
HY-L184
-
Anti-Brain Cancer Compound Library
HY-L188
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) BMS-1
More- Bioact Mater. 2024 May 23:39:239-254. [Abstract]
- Adv Funct Mater. 2021 Mar 21.
- Sci Transl Med. 2025 May 21;17(799):eadn7527. [Abstract]
- Acta Pharm Sin B. 2024 Feb;14(2):854-868. [Abstract]
- Adv Sci (Weinh). 2024 May;11(18):e2310163. [Abstract]
- J Exp Clin Cancer Res. 2022 Jan 3;41(1):1. [Abstract]
- Small. 2023 Jan;19(3):e2205694. [Abstract]
- J Control Release. 2024 Aug 20:374:230-241. [Abstract]
- J Control Release. 2023 May:357:460-471. [Abstract]
- J Immunother Cancer. 2020 Oct;8(2):e000293. [Abstract]
- J Colloid Interface Sci. 2022 May 15:614:436-450. [Abstract]
- Acta Biomater. 2024 Mar 15:177:414-430. [Abstract]
- ACS Appl Mater Interfaces. 2025 Jul 30;17(30):42893-42914. [Abstract]
- Biomed Pharmacother. 2021 Oct:142:111955. [Abstract]
- Int J Nanomedicine. 2023 Jul 31:18:4329-4346. [Abstract]
- Breast Cancer Res. 2025 May 26;27(1):92. [Abstract]
- Biochem Pharmacol. 2023 Jun:212:115582. [Abstract]
- Mol Neurobiol. 2023 May;60(5):2922-2936. [Abstract]
- Sci Rep. 2025 Dec 17. [Abstract]
- Sci Rep. 2025 Oct 22;15(1):36873. [Abstract]
- Aging (Albany NY). 2021 Jun 24;13(12):16656-16666. [Abstract]
- Mol Cell Biochem. 2025 Oct 15. [Abstract]
- Vaccine. 2019 Apr 3;37(15):2090-2098. [Abstract]
- J Biomed Mater Res B Appl Biomater. 2021 Feb;109(2):269-278. [Abstract]
- J Pharm Biomed Anal. 2025 Nov 23:270:117281. [Abstract]
- Curr Issues Mol Biol. 2026 Feb 10;48(2):195. [Abstract]
- Carcinogenesis. 2019 Sep 18;40(9):1132-1141. [Abstract]
- Mol Pain. 2024 Jan-Dec:20:17448069241252384. [Abstract]
- Gene. 2024 Jul 25:148796. [Abstract]
- In Vitro Cell Dev Biol Anim. 2024 Apr;60(4):382-396. [Abstract]
- Bios. 2026 Mar 31;97(1):71-78.
- bioRxiv. June 30, 2021.
Customer Validation & Images
-
WB
-
IF
-
IF
-
IF
Activité biologique
PD1-PDL1[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | EC50 |
52.3 μM
Compound: BMS-1
|
Cytotoxicity against CHO cells expressing human PD-L1 assessed as cell viability measured after 24 hrs by MTT assay
Cytotoxicity against CHO cells expressing human PD-L1 assessed as cell viability measured after 24 hrs by MTT assay
|
[PMID: 38442487] |
| Jurkat | IC50 |
18.4 μM
Compound: BMS-1
|
Cytotoxicity against human Jurkat cells incubated for 48 hrs by CCK-8 assay
Cytotoxicity against human Jurkat cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 33938739] |
Since PD-1 mediated the exhaustion of natural killer (NK) cell by binding to its ligand PD-L1, BMS-1 (PD-1/PD-L1 inhibitor 1) (1 μM, 3 days) is used to disturb the interaction between PD-1 and PD-L1. Dexamethasone induced increase of PD-1 expression and decrease of cytotoxicity of the co-cultured NK92 cells are reversed by BMS-1[1]. BMS-1, a small-molecule immune checkpoint inhibitor of PD-1/PD-L1, can be used as a therapeutic strategy for tumor immunotherapy[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:NK cells and HepG2 cells
-
Concentration:1 μM
-
Incubation Time:3 days
-
Result:Disturbed the interaction between PD-1 and PD-L1.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice with EMT6 cells[3]
-
Dosage:500 μg/mL; 100 μL
-
Administration:I.p.
-
Result:Increased the survival rates of the mVEGF165b group and mVEGF165b + MUC1 group.
mVEGF165b combined with MUC1 results significant retardation of the tumor growth.
Chemical Information
-
CAS No. 1675201-83-8
-
Appearance Solid
-
Masse moléculaire 475.58
-
Formule C29H33NO5
-
Color White to off-white
-
SMILES
O=C([C@H]1N(CC2=C(OC)C=C(OCC3=C(C)C(C4=CC=CC=C4)=CC=C3)C=C2OC)CCCC1)O
-
Synonyms
PD-1/PD-L1 inhibitor 1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (32)
-
Journal Impact Factor
-
Most Recent
-
Bioact Mater
Immunostimulatory CKb11 gene combined with immune checkpoint PD-1/PD-L1 blockade activates immune response and simultaneously overcomes the immunosuppression of cancer. [Abstract]2024 May 23:39:239-254. PMID: 38832303 -
-
Sci Transl Med
SARS-CoV-2 induces neutrophil degranulation and differentiation into myeloid-derived suppressor cells associated with severe COVID-19. [Abstract]2025 May 21;17(799):eadn7527. PMID: 40397714 -
Acta Pharm Sin B
Immunostimulatory gene therapy combined with checkpoint blockade reshapes tumor microenvironment and enhances ovarian cancer immunotherapy. [Abstract]2024 Feb;14(2):854-868. PMID: 38322330 -
Adv Sci (Weinh)
Metabolism/Immunity Dual-Regulation Thermogels Potentiating Immunotherapy of Glioblastoma Through Lactate-Excretion Inhibition and PD-1/PD-L1 Blockade. [Abstract]2024 May;11(18):e2310163. PMID: 38460167 -
J Exp Clin Cancer Res
Prevotellaceae produces butyrate to alleviate PD-1/PD-L1 inhibitor-related cardiotoxicity via PPARα-CYP4X1 axis in colonic macrophages. [Abstract]2022 Jan 3;41(1):1. PMID: 34980222 -
Small
Cascade Immune Activation of Self-Delivery Biomedicine for Photodynamic Immunotherapy Against Metastatic Tumor. [Abstract]2023 Jan;19(3):e2205694. PMID: 36366925 -
J Control Release
Chimeric peptide-engineered immunostimulant for endoplasmic reticulum targeted photodynamic immunotherapy against metastatic tumor. [Abstract]2024 Aug 20:374:230-241. PMID: 39151829 -
J Control Release
Targeting glutamine metabolism with photodynamic immunotherapy for metastatic tumor eradication. [Abstract]2023 May:357:460-471. PMID: 37068523 -
J Immunother Cancer
2020 Oct;8(2):e000293. PMID: 33037113 -
J Colloid Interface Sci
Low-temperature photothermal irradiation triggers alkyl radicals burst for potentiating cancer immunotherapy. [Abstract]2022 May 15:614:436-450. PMID: 35108635 -
Acta Biomater
Nanoparticle-mediated blockade of CXCL12/CXCR4 signaling enhances glioblastoma immunotherapy: Monitoring early responses with MRI radiomics. [Abstract]2024 Mar 15:177:414-430. PMID: 38360292 -
ACS Appl Mater Interfaces
Methacrylated Carrageenan/Gelatin Interpenetrating Network Microspheres Loaded with Targeted Drugs and combined with PD-L1 Inhibitors for Hepatocellular Carcinoma Treatment. [Abstract]2025 Jul 30;17(30):42893-42914. PMID: 40671639 -
Biomed Pharmacother
Immune checkpoint programmed death-1 mediates abdominal aortic aneurysm and pseudoaneurysm progression. [Abstract]2021 Oct:142:111955. PMID: 34339918 -
Int J Nanomedicine
Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment. [Abstract]2023 Jul 31:18:4329-4346. PMID: 37545872 -
Breast Cancer Res
NOTCH1 inhibition enhances immunogenicity and sensitizes triple-negative breast cancer to immune checkpoint inhibitors. [Abstract]2025 May 26;27(1):92. PMID: 40420289 -
Biochem Pharmacol
Targeting HMGA1 contributes to immunotherapy in aggressive breast cancer while suppressing EMT. [Abstract]2023 Jun:212:115582. PMID: 37146833 -
Mol Neurobiol
Electroacupuncture Alleviates CFA-Induced Inflammatory Pain via PD-L1/PD-1-SHP-1 Pathway. [Abstract]2023 May;60(5):2922-2936. PMID: 36753045
BMS-1 purchased from MedChemExpress. Usage Cited in: Mol Neurobiol. 2023 May;60(5):2922-2936. [Abstract]
BMS-1 (100 µg; Intrathecal injection; once every 2 days, for a total of four times) decreases the expression of SHP-1 in dorsal root ganglia of Male Sprague-Dawley (SD) rats.
BMS-1 purchased from MedChemExpress. Usage Cited in: Mol Neurobiol. 2023 May;60(5):2922-2936. [Abstract]
BMS-1 (50, 100 µg; Intrathecal injection; once every 2 days, for a total of four times) signifcantly reduces the expression of PD-L1 in CGRP+, neurons of Male Sprague-Dawley (SD) rats.
BMS-1 purchased from MedChemExpress. Usage Cited in: Mol Neurobiol. 2023 May;60(5):2922-2936. [Abstract]
BMS-1 (50, 100 µg; Intrathecal injection; once every 2 days, for a total of four times) signifcantly reduces the expression of PD-L1 in NF200+, neurons of Male Sprague-Dawley (SD) rats.
BMS-1 purchased from MedChemExpress. Usage Cited in: Mol Neurobiol. 2023 May;60(5):2922-2936. [Abstract]
BMS-1 (50, 100 µg; Intrathecal injection; once every 2 days, for a total of four times) signifcantly reduces the expression of PD-L1 in IB4+, neurons of Male Sprague-Dawley (SD) rats.
-
Sci Rep
PD-1/PD-L1 pathway relieves incision induced acute postoperative pain via inhibiting the neuroinflammation in dorsal root ganglion of rats. [Abstract]2025 Dec 17. PMID: 41408237 -
Sci Rep
Anti PD-L1 immunotherapy alters macrophage phenotypes via EGR1 and HSP90AB1 supported by integrated methodologies. [Abstract]2025 Oct 22;15(1):36873. PMID: 41125697 -
Aging (Albany NY)
2021 Jun 24;13(12):16656-16666. PMID: 34170847 -
Mol Cell Biochem
Inhibition of LSD1 enhances T cells anti-tumor immunity by promoting TNFSF14 expression in gastric cancer. [Abstract]2025 Oct 15. PMID: 41091427 -
Vaccine
Utilizing VEGF165b mutant as an effective immunization adjunct to augment antitumor immune response. [Abstract]2019 Apr 3;37(15):2090-2098. PMID: 30837171 -
J Biomed Mater Res B Appl Biomater
Inhibition of programmed death-1 decreases neointimal hyperplasia after patch angioplasty. [Abstract]2021 Feb;109(2):269-278. PMID: 32770622 -
J Pharm Biomed Anal
Identification of new small molecule inhibitors of PD-1/PD-L1 interaction by a comprehensive ligand fishing system. [Abstract]2025 Nov 23:270:117281. PMID: 41308584 -
Curr Issues Mol Biol
Walnut Green Husk Polysaccharide Improve Gut Microbiota and Alleviate Intestinal Inflammation Caused by Immune Checkpoint Inhibitors. [Abstract]2026 Feb 10;48(2):195. PMID: 41751457 -
Carcinogenesis
Depression Promotes Hepatocellular Carcinoma Progression through a Glucocorticoids Mediated Up-Regulation of PD-1 Expression in Tumor infiltrating NK Cells. [Abstract]2019 Sep 18;40(9):1132-1141. PMID: 30715244 -
Mol Pain
The regulation of the PD-1/PD-L1 pathway in imiquimod-induced chronic psoriasis itch and itch sensitization in mouse. [Abstract]2024 Jan-Dec:20:17448069241252384. PMID: 38631843 -
Gene
Identifying and validating angiogenesis-related genes remodeling tumor microenvironment and suppressing immunotherapy response in gastric cancer. [Abstract]2024 Jul 25:148796. PMID: 39067544 -
In Vitro Cell Dev Biol Anim
2024 Apr;60(4):382-396. PMID: 38625487 -
-
Solvant et solubilité
Methanol : 25 mg/mL (52.57 mM; Need ultrasonic)
DMSO : 7.14 mg/mL (15.01 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
DMF : 5 mg/mL (10.51 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.71 mg/mL (1.49 mM); Clear solution
This protocol yields a clear solution of ≥ 0.71 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (7.1 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.71 mg/mL (1.49 mM); Clear solution
This protocol yields a clear solution of ≥ 0.71 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (7.1 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 10 mg/mL (21.03 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Zhao Y, et al. Depression Promotes Hepatocellular Carcinoma Progression through a Glucocorticoids Mediated Up-Regulation of PD-1 Expression in Tumor infiltrating NK Cells. Carcinogenesis. 2019 Feb 4. [Content Brief]
[2]. Li K, et al. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy. J Drug Target. 2019 Mar;27(3):244-256. [Content Brief]
[3]. Zhang H, et al. Utilizing VEGF165b mutant as an effective immunization adjunct to augment antitumor immune response. Vaccine. 2019 Apr 3;37(15):2090-2098. [Content Brief]
[4]. Mengyuan Li, et al. KALRN mutations promote antitumor immunity and immunotherapy response in cancer. J Immunother Cancer. 2020 Oct;8(2):e000293. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMF / DMSO / Methanol | 1 mM | 2.1027 mL | 10.5135 mL | 21.0270 mL | 52.5674 mL |
| 5 mM | 0.4205 mL | 2.1027 mL | 4.2054 mL | 10.5135 mL | |
| 10 mM | 0.2103 mL | 1.0513 mL | 2.1027 mL | 5.2567 mL | |
| DMSO / Methanol | 15 mM | 0.1402 mL | 0.7009 mL | 1.4018 mL | 3.5045 mL |
| Methanol | 20 mM | 0.1051 mL | 0.5257 mL | 1.0513 mL | 2.6284 mL |
| 25 mM | 0.0841 mL | 0.4205 mL | 0.8411 mL | 2.1027 mL | |
| 30 mM | 0.0701 mL | 0.3504 mL | 0.7009 mL | 1.7522 mL | |
| 40 mM | 0.0526 mL | 0.2628 mL | 0.5257 mL | 1.3142 mL | |
| 50 mM | 0.0421 mL | 0.2103 mL | 0.4205 mL | 1.0513 mL |
Powered by Bioz